trending Market Intelligence /marketintelligence/en/news-insights/trending/_O48VAUnJT_NPqh1DkKtzw2 content esgSubNav
In This List

La Jolla's drug for low blood pressure wins FDA approval

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


La Jolla's drug for low blood pressure wins FDA approval

The U.S. Food and Drug Administration approved La Jolla Pharmaceutical Co.'s Giapreza to increase blood pressure in adults with septic or other distributive shock.

The agency advised that the drug can cause dangerous blood clots with serious consequences, and preventive treatment for blood clots should be used.

Shock is a life-threatening condition that occurs due to lack of blood flow and can result in organ failure and death.

La Jolla plans to make the drug available for patients in the U.S. in March 2018.